Ravinya Karunarathna on Importance of RBC Counting
Ravinya Karunarathna, BSc (Hons) in Biotechnology at Horizon Campus, shared on LinkedIn:
”RBC Counting Is How Serious Labs Turn Numbers Into decisions
RBC counting with a hemocytometer isn’t “just counting cells.”
It’s the point where technique, accuracy, and clinical interpretation meet.
Every step affects the final result — dilution, loading, focus, counting fields, and calculation.
Here’s the shift that matters
- It’s NOT about eyeballing cells
- It’s about standardized quantification per microliter using volume-defined grids
How RBC counting actually works
- Proper dilution (e.g., 1:200 with saline)
- Precise loading without overflow or bubbles
- Microscope focus from 4x → 40x for grid clarity
- Accurate grid-based counting → Convert to cells/mL
What the data reveals
- Anemia vs. normal vs. polycythemia ranges
- Dilution or loading errors in seconds
- Technician skill vs. process reliability
- Whether treatment or diagnosis is grounded in data
This is how teams measure:
- Baseline RBC levels
- Patient progress or treatment response
- Hematology sample quality and consistency
No assumptions
No “approximate” counts
No guessing through the microscope
Just standardized measurement based on volume, dilution and math If results look inconsistent, the issue is rarely the patient.
More often, it’s technique, dilution accuracy, or grid counting.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera